Aprogen Biologics Decides to Issue 50.8 Billion Won Convertible Bonds for Affiliate Debt Repayment, Raising Severe Dilution Concerns
Aprogen's subsidiary Aprogen Biologics has decided to issue 50.8 billion won in private convertible bonds to affiliates Apptochrom and Aprogen I&C.
The proceeds will be used to repay existing debts of the same amount from these affiliates, essentially a refinancing.
The conversion price is set at 2,353 won, a 9.9% discount to the current stock price, potentially issuing 21.59 million new shares representing 149.8% of outstanding shares, raising severe dilution concerns.
The conversion price can be adjusted downward to as low as 1,648 won if the stock price falls, increasing dilution risk.
The financial improvement for the subsidiary is limited, and the related-party nature of the transaction raises governance issues.
[AI Summary]The 50.8 billion won CB issuance by Aprogen Biologics is a defensive refinancing to repay affiliate debts, with potential massive dilution upon conversion. The discounted issuance and downward price adjustment clauses threaten shareholder value, and the lack of transparency in related-party transactions adds governance risk.
KOSPI Filing Information
[Correction of Description] Report On Major Matters (Decision On Issuance Of Convertible Bonds) (Major Management Matters Of Subsidiary)